Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
Roivant Sciences Ltd. (ROIV) reported that director Oren Ilan received equity awards on September 16, 2026 under the company's 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy. He was granted 10,531 stock options to purchase Common Shares at an exercise price of $39.57 per share, expiring on September 15, 2036, and 5,054 restricted stock units (RSUs) covering Common Shares. Both the RSUs and the stock options are scheduled to vest 100% on September 16, 2027, subject to his continued service as a director. Following the RSU grant, he directly owned 123,680 Common Shares.
Roivant Sciences Ltd. (ROIV) reported that director James C. Momtazee received equity awards on September 16, 2026. He was granted 5,054 RSUs covering Common Shares and a stock option for 10,531 shares at an exercise price of $39.57 per share. Both awards are scheduled to vest 100% on September 16, 2027, subject to his continued service as a director. Following these awards, he directly holds 111,959 Common Shares and an option to purchase 10,531 shares. No Rule 10b5-1 trading plan is reported.
Roivant Sciences Ltd. (ROIV) reported that director Meghan Fitzgerald received equity-based compensation on September 16, 2026. She was granted 10,531 stock options to purchase Common Shares at an exercise price of $39.57 per share, expiring on September 15, 2036, and 5,054 restricted stock units (RSUs) for Common Shares.
Both the RSUs and the stock options were granted under Roivant’s 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy and are scheduled to vest 100% on September 16, 2027, subject to her continued service as a director. After the RSU grant, she directly holds 41,162 Common Shares. No Rule 10b5-1 trading plan is reported.
Roivant Sciences Ltd. (ROIV) reported that director Melissa B. Epperly received annual equity awards on September 16, 2026. She was granted 10,531 stock options to purchase Common Shares at an exercise price of $39.57 per share and 5,054 restricted stock units, all as direct holdings. The RSUs and the options are scheduled to vest 100% on September 16, 2027, subject to her continued service as a director. Following these awards, she directly holds 14,954 Common Shares and 10,531 options.
Roivant Sciences Ltd. (ROIV) reported the results of its 2026 Annual General Meeting of Shareholders held on September 16, 2026. Of 722,406,273 common shares outstanding and entitled to vote as of July 23, 2026, holders of 652,143,869 shares (approximately 90.3%) were present in person or by proxy, constituting a quorum.
Shareholders re-elected Daniel Gold and Meghan FitzGerald as Class II directors to serve until the annual general meeting following the fiscal year ending March 31, 2029, with Gold receiving 375,791,264 votes for and FitzGerald 422,428,908 votes for. Shareholders also ratified Ernst & Young LLP as independent registered public accounting firm and Bermuda statutory auditor for the fiscal year ending March 31, 2027, with 651,315,490 votes for. On a non-binding advisory basis, shareholders approved the compensation of the named executive officers with 316,702,500 votes for and 269,062,122 against.
Roivant Sciences Ltd. (ROIV) director Melissa B. Epperly reported open-market sales of Roivant Common Shares on September 15, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. She sold 4,338 shares at a weighted average price of $39.65 and 600 shares at a weighted average price of $40.38, with each sale executed in multiple trades within disclosed price ranges.
Roivant Sciences Ltd. (ROIV) director Meghan Fitzgerald reported open-market sales of Roivant common shares. On September 15, 2026, she sold 4,712 shares at a weighted average price of $39.68 per share and 400 shares at a weighted average price of $40.45 per share. The prices reflect multiple trades in ranges of $39.26–$40.25 and $40.28–$40.51, respectively, and all sales were effected under a Rule 10b5-1 trading plan adopted on March 30, 2026.
Roivant Sciences Ltd. (ROIV) director Melissa Epperly has filed a Form 144 indicating an intent to sell up to 22,688 shares of common stock through Morgan Stanley Smith Barney LLC, with an estimated aggregate market value of $930,661.76 as of September 15, 2026. The planned sales include shares to be received from the exercise of stock options for 17,750 shares dated September 15, 2026 and from restricted stock units for 4,938 shares dated September 10, 2026. The notice states the securities to be sold will be received upon option exercises over the next three months, and that the dates of acquisition and payment will be the dates of exercise or sale. Epperly previously sold 17,750 shares of Roivant common stock on June 29, 2026 for $610,188.20 under a 10b5-1 trading plan.
Roivant Sciences Ltd. (ROIV) received a notice under Rule 144 that officer Meghan Fitzgerald plans to sell 5,112 shares of common stock, held at Morgan Stanley Smith Barney LLC Executive Financial Services. The shares relate to Restricted Stock Units from the issuer dated September 10, 2026.
The notice also lists prior Rule 10b5-1 sales of 20,000 shares for $798,010.00 on September 8, 2026 and 10,000 shares for $349,000.00 on June 30, 2026.
Roivant Sciences Ltd. (ROIV) reported that director Daniel Allen Gold had 5,133 Common Shares withheld on September 10, 2026 to satisfy tax withholding obligations in connection with the vesting and settlement of previously granted shares under the Non-Employee Director Compensation Plan. After this net-share tax withholding, he holds 8,960,761 Common Shares directly.